SERGEF

Across TCGA pan-cancer cohorts, SERGEF Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SERGEF data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SERGEF Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SERGEF expression acts as an unfavorable survival marker.

LUSC, COAD, and LUAD are the cancer types where SERGEF Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.249	0.662	.010	18	view →
COAD	OS	Median	All	0.168	0.806	.002	12	view →
LUAD	OS	Median	All	0.333	0.700	.022	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SERGEF–LUSC (DFS)

Open the LUSC breakdown →